FDA warns Guangzhou Four E’s over CGMP failures for OTC drugs, including a sterile-labeled product with inadequate sterility assurance.
What happened
FDA reviewed records the company submitted after a March 4, 2024 request under section 704(a)(4) of the FD&C Act. The review found the quality unit did not adequately oversee a contract manufacturer and did not ensure product quality. It also found a product labeled sterile had contract manufacturer specifications using aerobic plate count rather than USP <71> sterility, and the contract manufacturer had CGMP violations that led to an import alert.
What FDA found
The quality control unit did not ensure drugs met CGMP and established specifications for identity, strength, quality, and purity.
21 CFR 211.22The quality unit lacked adequate oversight and procedures for the contract manufacturer to ensure CGMP compliance.
21 CFR 211.22The company used a contract manufacturer to make, process, and package drugs, received the products, and declared itself as manufacturer on import records.
A product labeled sterile had contract manufacturer specifications using aerobic plate count, not USP <71> sterility testing.
USP <71>The contract manufacturer had inadequate raw material testing, incomplete process validation, and inadequate finished product testing.
21 CFR parts 210 and 211The company did not ensure its drugs were made under CGMP despite agreements with contract facilities.
FD&C Act section 501(a)(2)(B)
What FDA wants
FDA asks the company to provide a comprehensive assessment and remediation plan to give its quality unit authority and resources, evaluate the drug product specifications, and respond in writing within 15 working days with corrective actions or a schedule.
Who should pay attention
- companies relying on contract manufacturers for sterile OTC drugs
- importers and brands that list foreign manufacturers on import records
- quality and regulatory teams managing CMO quality agreements
This is a summary. Read the original letter on fda.gov.